CNC Quote, Financials, Valuation and Earnings

The Cigna Group has a net margin of 0.69% compared to Centene's net margin of 2.17%. Centene's return on equity of 12.3% beat The Cigna Group's return on equity of 8.07%.

Centene has a consensus price target of $79.27, signalling upside risk potential of 27.04%. On the other hand The Cigna Group has an analysts' consensus of $362.55 which suggests that it could grow by 15.52%. Given that Centene has higher upside potential than The Cigna Group, analysts believe Centene is more attractive than The Cigna Group.

Centene has a beta of 0.529, which suggesting that the stock is 47.066% less volatile than S&P 500. In comparison The Cigna Group has a beta of 0.506, suggesting its less volatile than the S&P 500 by 49.385%.

Centene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Cigna Group offers a yield of 1.82% to investors and pays a quarterly dividend of $1.51 per share. Centene pays -- of its earnings as a dividend. The Cigna Group pays out 45.63% of its earnings as a dividend. The Cigna Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Centene quarterly revenues are $40.8B, which are smaller than The Cigna Group quarterly revenues of $65.7B. Centene's net income of $283M is lower than The Cigna Group's net income of $1.4B. Notably, Centene's price-to-earnings ratio is 10.00x while The Cigna Group's PE ratio is 25.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centene is 0.20x versus 0.36x for The Cigna Group. Usually stocks with elevated PS ratios are considered overvalued.

Elevance Health has a net margin of 0.69% compared to Centene's net margin of 0.92%. Centene's return on equity of 12.3% beat Elevance Health's return on equity of 14.4%.

Centene has a consensus price target of $79.27, signalling upside risk potential of 27.04%. On the other hand Elevance Health has an analysts' consensus of $498.97 which suggests that it could grow by 15.8%. Given that Centene has higher upside potential than Elevance Health, analysts believe Centene is more attractive than Elevance Health.

Centene has a beta of 0.529, which suggesting that the stock is 47.066% less volatile than S&P 500. In comparison Elevance Health has a beta of 0.773, suggesting its less volatile than the S&P 500 by 22.685%.

Centene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Elevance Health offers a yield of 1.53% to investors and pays a quarterly dividend of $1.71 per share. Centene pays -- of its earnings as a dividend. Elevance Health pays out 25.22% of its earnings as a dividend. Elevance Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Centene quarterly revenues are $40.8B, which are smaller than Elevance Health quarterly revenues of $45.4B. Centene's net income of $283M is lower than Elevance Health's net income of $418M. Notably, Centene's price-to-earnings ratio is 10.00x while Elevance Health's PE ratio is 16.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centene is 0.20x versus 0.57x for Elevance Health. Usually stocks with elevated PS ratios are considered overvalued.

Molina Healthcare has a net margin of 0.69% compared to Centene's net margin of 2.39%. Centene's return on equity of 12.3% beat Molina Healthcare's return on equity of 25.84%.

Centene has a consensus price target of $79.27, signalling upside risk potential of 27.04%. On the other hand Molina Healthcare has an analysts' consensus of $338.46 which suggests that it could grow by 2.36%. Given that Centene has higher upside potential than Molina Healthcare, analysts believe Centene is more attractive than Molina Healthcare.

Centene has a beta of 0.529, which suggesting that the stock is 47.066% less volatile than S&P 500. In comparison Molina Healthcare has a beta of 0.701, suggesting its less volatile than the S&P 500 by 29.866%.

Centene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Molina Healthcare offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Centene pays -- of its earnings as a dividend. Molina Healthcare pays out -- of its earnings as a dividend.

Centene quarterly revenues are $40.8B, which are larger than Molina Healthcare quarterly revenues of $10.5B. Centene's net income of $283M is higher than Molina Healthcare's net income of $251M. Notably, Centene's price-to-earnings ratio is 10.00x while Molina Healthcare's PE ratio is 16.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centene is 0.20x versus 0.47x for Molina Healthcare. Usually stocks with elevated PS ratios are considered overvalued.

UnitedHealth Group has a net margin of 0.69% compared to Centene's net margin of 5.5%. Centene's return on equity of 12.3% beat UnitedHealth Group's return on equity of 14.34%.

Centene has a consensus price target of $79.27, signalling upside risk potential of 27.04%. On the other hand UnitedHealth Group has an analysts' consensus of $629.92 which suggests that it could grow by 13.72%. Given that Centene has higher upside potential than UnitedHealth Group, analysts believe Centene is more attractive than UnitedHealth Group.

Centene has a beta of 0.529, which suggesting that the stock is 47.066% less volatile than S&P 500. In comparison UnitedHealth Group has a beta of 0.607, suggesting its less volatile than the S&P 500 by 39.293%.

Centene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UnitedHealth Group offers a yield of 1.52% to investors and pays a quarterly dividend of $2.10 per share. Centene pays -- of its earnings as a dividend. UnitedHealth Group pays out 52.29% of its earnings as a dividend. UnitedHealth Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Centene quarterly revenues are $40.8B, which are smaller than UnitedHealth Group quarterly revenues of $100.8B. Centene's net income of $283M is lower than UnitedHealth Group's net income of $5.5B. Notably, Centene's price-to-earnings ratio is 10.00x while UnitedHealth Group's PE ratio is 35.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centene is 0.20x versus 1.28x for UnitedHealth Group. Usually stocks with elevated PS ratios are considered overvalued.